Announced Fri, 11 Sept, 2026 · 13:25 IST
Shilpa Medicare gets SEC nod for OERIS injectable marketing authorization
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.4%1-day move
₹943.00
prior close
₹948.30
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.0+1.5+1.9+1.0-3.4-0.8+1.4+9.0+13.2+10.1+14.1———
Up moveDown movePending
AI summary
OERIS (Ondansetron Extended-Release Injection) received final SEC approval for marketing authorization. Worlds first extended-release ondansetron injectable, offering 5-day antiemetic action from a single dose for chemotherapy patients. Backed by a successful Phase III trial. Patent protected in India until 2039. Commercial launch planned across India.
Likely market impact
Positive - novel oncology product approval strengthens specialty pharma portfolio and opens commercial revenue opportunity.